Valproate-induced hyperammonemic encephalopathy.
Yehya
Nadir
N
Saldarini
Candace Tom
CT
Koski
Michelle E
ME
Davanzo
Pablo
P
D000374:Aggression / Q000187:drug effects; D000927:Anticonvulsants / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D019958:Attention Deficit and Disruptive Behavior Disorders / Q000097:blood / Q000139:chemically induced / Q000175:diagnosis; D002648:Child; D003937:Diagnosis, Differential; D003987:Dibenzothiazepines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D007174:Disruptive, Impulse Control, and Conduct Disorders / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004569:Electroencephalography / Q000187:drug effects; D006801:Humans; D022124:Hyperammonemia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis; D018021:Lithium Chloride / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity; D008111:Liver Function Tests; D008297:Male; D020258:Neurotoxicity Syndromes / Q000097:blood / Q000175:diagnosis*; D000069348:Quetiapine Fumarate; D014635:Valproic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*
D000927:Anticonvulsants; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate; D014635:Valproic Acid; D018021:Lithium Chloride